Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.
Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.
Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.
ExchangeRight Income Fund sold 16,740 Class D Common Shares for gross proceeds of $462,000 between October 8 and October 21, 2026. The sale is part of an ongoing continuous private placement offering of up to $2.165 billion in common shares.
Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
Arcosa, Inc. completed its merger with CRH Americas, Inc., a subsidiary of CRH plc, resulting in Arcosa becoming a wholly owned subsidiary of CRH. Under the terms of the agreement, Arcosa stockholders received $150.00 in cash for each share of common stock held. In connection with the closing, Arcosa terminated its $1.4 billion senior secured credit facility and repaid approximately $450.1 million in outstanding obligations.
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
Crh Public Ltd Signs $8.5B M&A Deal with Arcosa, Inc.
CRH completed its acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products, for an enterprise value of approximately $8.5 billion. The deal reinforces CRH's position as the top infrastructure player in North America and increases its exposure to major road, water, energy, and data projects.
Value
$8.5B
Counterparty
Arcosa, Inc.
“Arcosa is an excellent strategic fit for CRH and fully aligns with our growth ambitions. With high-quality aggregates assets and attractive positions in the growing U.S. energy transmission market, the acquisition strengthens our connected portfolio and reinforces our position as the #1 infrastructure player in North America. We look forward to welcoming our Arcosa colleagues into CRH and executing on the strong growth opportunities ahead.”
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.
Nordson Signs $168M M&A Deal with Contrinex Holding SA
Nordson Corporation, through its subsidiary Nordson London Limited, completed the acquisition of Switzerland-based Contrinex Holding SA for an enterprise value of approximately $168 million. Contrinex is a global leader in high-performance sensors for factory automation, generating approximately $50 million in annual revenue, and will be integrated into Nordson’s Advanced Technology Solutions segment.
TPG Private Equity Opportunities Capital Raise of $73.1M
TPG Private Equity Opportunities, L.P. raised $73.1 million in aggregate consideration through the sale of unregistered limited partnership units on October 1, 2026. The sale was part of the Fund's continuous private offering and included Class I, Class S, and Class F units. The broader T-POP Fund Complex issued interests totaling approximately $103.2 million during the same period.
ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.
Intelligent Protection Management Signs $2.7M M&A Deal with Advanced Technology Distributors Inc.
Intelligent Protection Management Corp. (IPM) has entered into a definitive agreement to acquire the managed services business of Advanced Technology Distributors Inc. (AdTech) for up to $2.7 million. The transaction is structured in two stages, with IPM initially acquiring a 49% stake in a newly formed subsidiary (JVCo) followed by the remaining 51% upon receiving regulatory approvals from the California Public Utilities Commission. The deal aims to expand IPM's managed technology solutions and cybersecurity capabilities into the California market.
Tango Therapeutics announced updated Phase 1/2 clinical trial results for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The data demonstrated a 9-month progression-free survival rate of 88%, leading the company to plan a registrational Phase 3 trial in the first half of 2027.
Ftai Infrastructure Signs $255M M&A Deal with DRUbit LLC
FTAI Infrastructure's subsidiary Jefferson is providing a status update on its $255 million acquisition of DRUbit LLC from US Development Group. Jefferson plans to incur $270 million in new debt to fund the deal and expects the acquired assets to contribute $50 million in annual Adjusted EBITDA, effectively doubling Jefferson's total annual Adjusted EBITDA to approximately $100 million.
Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.
Zai Lab Limited entered into a securities purchase agreement with accredited investors for a private placement (PIPE) of 11,340,000 American depositary shares (ADSs). The company expects to receive gross proceeds of approximately $250 million to fund pipeline development and general corporate purposes. The ADSs are priced at $22.04 each, and the company has agreed to file a registration statement for the resale of these securities.
S&P Global Inc. provided pro forma financial statements following the completed spin-off of its S&P Global Mobility segment into an independent public company, Mobility Global Inc. (NYSE: MBGL). The separation was executed via a pro rata distribution of one share of Mobility Global for every share of S&P Global held as of the June 15, 2026 record date.
Inflection Point Acquisition Corp. VI M&A Deal with Quantum Space, LLC
Inflection Point Acquisition Corp. VI entered into an amendment to its existing business combination agreement with Quantum Space, LLC. The amendment changes the intended listing exchange for the post-combination company from Nasdaq to the New York Stock Exchange (NYSE) and modifies the requirements for the post-closing board of directors composition.
Lunai Bioworks received a Nasdaq delisting determination for failing to maintain the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $9 million. The company has decided not to appeal the decision and will voluntarily delist its common stock from Nasdaq and deregister with the SEC to save costs.
Black Hills M&A Deal with NorthWestern Energy Group, Inc.
Black Hills Corp. provided a status update on its pending merger with NorthWestern Energy, announcing that the combined entity will be renamed Bright Horizon Energy Corporation and trade under the ticker 'HZN' upon closing. The merger is currently awaiting final regulatory approval from the Montana Public Service Commission, which is expected to consider the deal by November 12, 2026.
Grown Rogue International announced its commercial entry into the Illinois cannabis market through its affiliate SEA Craft LLC, which completed its first product deliveries to select dispensaries. The launch follows the June 2026 restart of the Dwight cultivation facility, which currently operates 5,000 square feet of flowering canopy with plans to expand to 10,000 square feet.
Valor Energy Signs $3.6M M&A Deal with Glorious Star LLC
Valor Energy Inc. entered into a definitive agreement to acquire 100% of the equity interests of Glorious Star LLC (the Target Company) for an aggregate purchase price of $3.6 million. The Target Company holds site ownership and development rights for a computing center project in Youngstown, Ohio, featuring 18 MVA of power capacity and approximately 30,888 square feet of warehouse space. The deal is subject to a 30-business-day due diligence period and is expected to close shortly thereafter.
PAVmed's subsidiary, Lucid Diagnostics Inc., completed a private placement of 15,000 shares of Series C Convertible Preferred Stock to accredited investors. The offering generated gross proceeds of $15.0 million at a purchase price of $1,000 per share. Lucid Diagnostics also entered into a registration rights agreement to facilitate the resale of common stock issuable upon conversion of the preferred shares.
Frazier Life Sciences Acquisition Corp. II Capital Raise of $78M
Frazier Life Sciences Acquisition Corp. II completed its initial public offering of 7,500,000 Class A ordinary shares and a simultaneous private placement of 300,000 shares to its sponsor, generating total gross proceeds of $78 million. Of these proceeds, $75 million was deposited into a U.S.-based trust account for the benefit of public shareholders.
BranchOut Food Inc. has commenced an underwritten public offering of its common stock to fund operating plans and growth initiatives. Alongside the offering, the company provided a business update expecting record Q4 revenue of $6M–$7M and a recurring revenue base of approximately $4M per quarter heading into 2027.
NeOnc Technologies reported early clinical improvement in the first pediatric patient treated with its investigational intranasal NEO100 under a Compassionate Care program in Abu Dhabi. The company also announced a Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on oncology and CNS therapeutic research.
DevvStream Legacy Corp. completed its business combination with XCF Global, Inc. on October 16, 2026, following its domestication as a Delaware corporation. Under the terms of the agreement, DevvStream shareholders received 1.1919 shares of XCF Class A common stock for each share held, resulting in the issuance of approximately 62.3 million XCF shares.
Disc Medicine closed an underwritten public offering of 6,000,000 shares of common stock at a price of $75.00 per share, generating gross proceeds of $450 million. The company expects the net proceeds to extend its cash runway into 2030, supporting the clinical development and potential commercialization of its hematologic disease treatments, including bitopertin.
XCF Global M&A Deal with Southern Energy Renewables Inc. and DevvStream Corp.
XCF Global, Inc. completed its previously announced all-stock business combination with Southern Energy Renewables and DevvStream Corp. on October 16, 2026. The transaction creates a vertically integrated alternative energy platform, with former Southern and DevvStream equity holders owning approximately 20.0% and 10.43% of the combined company, respectively.
Counterparty
Southern Energy Renewables Inc. and DevvStream Corp.
“Today marks an important milestone for XCF as we bring together renewable fuel production, new technology pathways and environmental-asset optimization capabilities on one vertically integrated platform. This combination expands our capabilities and supports our strategy to reduce emissions, enhance energy security and resilience, promote alternative uses for domestic agricultural resources, locate production closer to demand and pursue additional value across the alternative renewable fuels chain across our growing glob”
Chris Cooper, Chief Executive Officer of XCF Global
Atlantic American Corporation received a staff delisting determination from Nasdaq on October 16, 2026, due to its failure to timely file its 2025 Annual Report and two subsequent 2026 Quarterly Reports. The company has since filed its 2025 Form 10-K and intends to appeal the delisting notice by requesting a hearing before a Nasdaq Hearings Panel to stay the suspension of its common stock. The company is working to file the remaining delinquent reports to regain compliance with Nasdaq Listing Rule 5250(c)(1).